Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1

Ann Clin Transl Neurol. 2020 Feb;7(2):245-249. doi: 10.1002/acn3.50976. Epub 2020 Feb 5.

Abstract

Cognitive problems are common in children with neurofibromatosis type 1, representing a significant source of lifelong morbidity. Assessment of cognitive function has been challenging in the setting of clinical trials. Spatial learning deficits may be an important target for cognitive interventions. We leveraged a large, international cognitive study in affected children with NF1 treated with lovastatin to assess spatial learning using the "Arena Maze", a portable, computerized task that allows for retesting in the same environment. As with the parent study, spatial learning assessed with this task did not improve with lovastatin treatment.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Child
  • Cognitive Dysfunction / diagnosis*
  • Cognitive Dysfunction / drug therapy
  • Cognitive Dysfunction / etiology*
  • Feasibility Studies
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Lovastatin / pharmacology
  • Male
  • Maze Learning / drug effects
  • Maze Learning / physiology
  • Neurofibromatosis 1 / complications*
  • Neurofibromatosis 1 / drug therapy
  • Neuropsychological Tests*
  • Spatial Learning / drug effects
  • Spatial Learning / physiology*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lovastatin